Case Report

Rivaroxaban-induced acute pancreatitis

Volume: 5 Number: 3 May 4, 2019
EN

Rivaroxaban-induced acute pancreatitis

Abstract

Rivaroxaban is a direct factor Xa inhibitor and has been safely used since 2008. It is used for the detection of atrial fibrillation and venous thromboembolism. Pancreatitis is one of the rare but dangerous side effects of rivaroxaban. The case of a 53-year-old female patient that developed in the third month of drug usage was evaluated, and it was confirmed after a full analysis was conducted that excluded all other factors, such as biliary calculus, alcohol usage, hypertriglyceridemia, biochemical parameters, ultrasonography and computed tomography that the patient’s condition was caused by the use of Rivaroxaban. The aim of this case presentation is to indicate that awareness should be increased regarding the risks of using the drug Rivaroxaban, as it could lead to drug-induced pancreatitis, even though this is rare. 

Keywords

References

  1. [1] Cappell MS. Acute pancreatitis: etiology, clinical presentation, diagnosis, and therapy. Med Clin North Am 2008;92:889-923.
  2. [2] Badalov N, Baradarian R, Iswara K, Li J, Steinberg W, Tenner S. Drug-induced acute pancreatitis:an evidence-based review. Clin Gastroenterol Hepatol 2007;5:648-61.
  3. [3] http://www.ehealthme.com/ds/xarelto/pancreatitis/
  4. [4] Tenner S. Drug induced acute pancreatitis: Does it exist? World J Gastroenterol 2014;20:16529-34.
  5. [5] Hung WY, Abreu Lanfranco O. Contemporary review of drug-induced pancreatitis: A different perspective. World J Gastrointest Pathophysiol 2014;5:405-15.

Details

Primary Language

English

Subjects

Health Care Administration

Journal Section

Case Report

Publication Date

May 4, 2019

Submission Date

April 24, 2018

Acceptance Date

October 8, 2018

Published in Issue

Year 2019 Volume: 5 Number: 3

APA
Sirkeci, Ö., Erkuş Sirkeci, E., & Taşel, B. (2019). Rivaroxaban-induced acute pancreatitis. The European Research Journal, 5(3), 569-571. https://doi.org/10.18621/eurj.417972
AMA
1.Sirkeci Ö, Erkuş Sirkeci E, Taşel B. Rivaroxaban-induced acute pancreatitis. Eur Res J. 2019;5(3):569-571. doi:10.18621/eurj.417972
Chicago
Sirkeci, Özgür, Emel Erkuş Sirkeci, and Belma Taşel. 2019. “Rivaroxaban-Induced Acute Pancreatitis”. The European Research Journal 5 (3): 569-71. https://doi.org/10.18621/eurj.417972.
EndNote
Sirkeci Ö, Erkuş Sirkeci E, Taşel B (May 1, 2019) Rivaroxaban-induced acute pancreatitis. The European Research Journal 5 3 569–571.
IEEE
[1]Ö. Sirkeci, E. Erkuş Sirkeci, and B. Taşel, “Rivaroxaban-induced acute pancreatitis”, Eur Res J, vol. 5, no. 3, pp. 569–571, May 2019, doi: 10.18621/eurj.417972.
ISNAD
Sirkeci, Özgür - Erkuş Sirkeci, Emel - Taşel, Belma. “Rivaroxaban-Induced Acute Pancreatitis”. The European Research Journal 5/3 (May 1, 2019): 569-571. https://doi.org/10.18621/eurj.417972.
JAMA
1.Sirkeci Ö, Erkuş Sirkeci E, Taşel B. Rivaroxaban-induced acute pancreatitis. Eur Res J. 2019;5:569–571.
MLA
Sirkeci, Özgür, et al. “Rivaroxaban-Induced Acute Pancreatitis”. The European Research Journal, vol. 5, no. 3, May 2019, pp. 569-71, doi:10.18621/eurj.417972.
Vancouver
1.Özgür Sirkeci, Emel Erkuş Sirkeci, Belma Taşel. Rivaroxaban-induced acute pancreatitis. Eur Res J. 2019 May 1;5(3):569-71. doi:10.18621/eurj.417972

Cited By